Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCR Medical
Stock Code01515
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities本集团是中国最大的私立医院集团,通过健宫医院提供综合医院服务,以IOT模式管理和运营多家医院及诊所并收取管理费,同时为医院网络提供药品、医疗器械及医用耗材的供应链业务。
Listing Date2013-11-29
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)北京西城區太平街6號E-825
Business Address (Hong Kong)香港金鐘道88號太古廣場二座1214-1215室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitephg.com.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 7.38 / shares
Offer Price RangeTo be extracted
Lot Size500 shares
Entry ThresholdTo be extracted
Par ValueRMB 0.00025 / shares
Offer Period2013-11-18 to 2013-11-21
Global Offering Shares200,907,000 shares
HK Public Offer Shares (Initial)20,091,000 shares (10.0%)
Public Offer Lots (Initial)40,182lots (Pool A20,091lots,Pool B20,091lots)
International Placing Shares (Initial)180,816,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO803,627,000 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,482,693,660

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 3.47B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +179%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币1.107亿元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 107,000,000
Listing Expenses / Funds Raised~7.22%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2010201120122013-06
Revenue 394,085509,478758,032419,692
Cost of sales -301,164-386,729-573,228-332,268
Gross profit 92,921122,749184,80487,424
Other income and gains, net 2,7358,28637,58427,545
Selling and distribution expenses -834-3,426-6,412-4,747
Administrative expenses -25,663-29,326-43,500-25,107
Net finance costs -2,997-18,858-24,379-11,531
Profit before tax 65,03278,718147,27870,161
Income tax expense -16,023-20,217-36,544-17,745
Profit for the year 49,00958,501110,73452,416
Profit attributable to owners 42,81248,130101,08850,354
Balance Sheet
Item 2010201120122013-06
Cash and cash equivalents 74,675330,988113,124128,246
Trade and bills receivables 20,10023,84583,010110,518
Inventories 22,26723,20035,07330,249
Total current assets 409,821489,798365,211535,549
Total assets 664,3101,134,6781,020,8601,184,400
Total current liabilities 144,835328,286202,369565,681
Total liabilities 357,424338,739443,102804,710
Total equity 306,886795,939577,758379,690
Equity attributable to owners 283,261591,779485,256285,126
Interest-bearing borrowings 200,000200,000233,074231,765
Cash Flow Statement
Item 2010201120122013-06
Net cash from operating activities 70,05762,352166,41972,065
Net cash from investing activities -328,099-36,120-102,200-58,076
Net cash from financing activities 298,011230,081-282,0831,598
Net increase in cash 39,969256,313-217,86415,587
Depreciation of PP&E 16,05714,70720,32510,466
Amortisation of intangible assets 1,5163,16812,3766,945
Purchase of PP&E -17,157-34,347-28,115-6,664
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 10.0
First Day OpenHK$ 8.58
First Day Change35.50%
First Day Volume210640000.0
First Day Turnover1968700000.0
Use of Proceeds
1、募集資金凈額的42%或58100萬元,將為本集團醫院網絡的擴展(透過公私合營和收購進行,以北京為策略重點)提供資金 2、募集資金凈額的25%或34000萬元,將就Speed Key Limited向債券持有人發行的可交換債券,以12%的年利率悉數償還本集團主要股東Speed Key Limited的未償還貸款 3、募集資金凈額的10%或10100萬元,將在2015年前作出資本支出,為健宮醫院重建若干設施及購買醫療設備 4、募集資金凈額的7%或34000萬元,將在2015年前,在集團層面建立先進的臨床測試及實驗中心 5、募集資金凈額的6%或8000萬元,將在2015年前向燕化醫院集團支付資本承擔 6、募集資金凈額的10%或13800萬元,將用于營運資金及其他一般企業用途

Underwriting Syndicate

Joint Sponsors (2)
DEUTSCHE SECURITIES ASIA LIMITED CE AAJ984 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (2)
Deutsche Bank AG, Hong Kong Branch CE AAK077 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Joint Bookrunners (3)
Deutsche Bank AG, Hong Kong Branch CE AAK077 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 交银国际证券有限公司 CE APJ121
Joint Lead Managers (3)
Deutsche Bank AG, Hong Kong Branch CE AAK077 GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 交银国际证券有限公司 CE APJ121

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman梁洪澤—
Company Secretary柯永基—
No director data available.

Major Shareholders

Major Shareholders & Holdings徐小捷女士通过Speed Key Limited持股34.51%,朱志偉先生通过升萬投資等持股22.29%,梁洪澤先生通过Hyde International持股7.76%,Greenwoods Bloom Fund通过Green Talent持股7.31%。
About this page

This page shows CR Medical (01515) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect